In light of the Government's announcement of an extension to article 50, ABPI commented on the position regarding stockpiling of medicines in preparation for a 'no-deal'.
The Department of Health and Social Care today published the 2019 update of their Implementation Plan for England for the UK Strategy for Rare Diseases. This sets out progress made against the original commitments in the Strategy.
King’s College London, Wellcome and pharmaceutical company MSD announced a collaboration and licencing deal today that could lead to a new class of pain medications.
“Pharmaceutical companies have done everything in their power to prepare for a ‘no deal’ Brexit. This includes increasing stocks of medicines, changing and adding new supply routes and duplicating manufacturing processes here and in Europe." MORE >
A Europe-wide initiative to protect patients and public health from falsified or fake medicines goes live on Saturday 9 February 2019, making the medicines supply chain across Europe safer than ever before.
The Chancellor has announced a £100 million investment for research and technology.
As the UK prepares to leave the EU, the House of Lords is debating a Statutory Instrument which would weaken the UK’s IP framework and damage the country’s reputation as leader in life sciences.
Lisa Anson, President of the ABPI, closing remarks to the ABPI Annual Conference on the future of UK life sciences.
Mike Thompson, chief executive of the ABPI, opening address to the ABPI Annual Conference outlining the strength of the industry and looking ahead to the next 70 years.
A report published by the Business, Energy and Indsutrial Strategy (BEIS) Strategy Committee, calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry.